Highlights Lipocine Inc.

Equities

LPCN

US53630X2036

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-26 pm EDT			5-day change	1st Jan Change
4.798 ^USD	+5.44%		-8.96%	+71.96%

Apr. 12	Lipocine Says LPCN 2401 Shows Improved Body Composition in Mid-Stage Trial	MT
Apr. 11	Top Premarket Gainers	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Lipocine Says LPCN 2401 Shows Improved Body Composition in Mid-Stage Trial	Apr. 12	MT
Top Premarket Gainers	Apr. 11	MT
Lipocine Inc. Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity	Apr. 11	CI
Lipocine Inc. Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis	Mar. 28	CI
Lipocine Doses First Group in Pivotal Study of Potential Postpartum Depression Drug	Mar. 25	MT
Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154	Mar. 25	CI
Lipocine Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 07	CI
Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154	Feb. 06	CI
Lipocine and Verity Pharma Enter into License Agreement for Tlando® Franchise in the U.S. and Canada	Jan. 18	CI
Lipocine Inc. Announces Results of its Phase 2 Study Evaluating LPCN 1148	Nov. 13	CI
Lipocine Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
Lipocine Inc. Completes Successful Meeting with FDA on LPCN 1154 in Postpartum Depression	23-10-26	CI
Lipocine Inc. Enters into License Agreement with Antares Pharma, Inc	23-10-06	CI
Lipocine Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Lipocine Inc. Announces Positive Topline Results from A Phase 2 Clinical Study of LPCN 1148	23-07-27	CI
Lipocine Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Earnings Flash (LPCN) LIPOCINE Reports Q1 Revenue $54,990	23-05-11	MT
Lipocine Inc. Doses First Participent in the Clinical Bridge Study with Lipocine Depression Candidate, LPCN 1154	23-04-03	CI
Lipocine Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-10	CI
Lipocine Inc. Completes Enrollment of LPCN 1148 Phase 2 Study for Decompensated Cirrhosis	22-12-19	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Lipocine Inc.

Equities

LPCN

US53630X2036

Highlights

Filters